Leon Nanodrugs
Series D in 2024
Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through advanced nanotechnology. The company develops a pipeline of improved drug products aimed at increasing the bioavailability of poorly water-soluble medicines. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates both polymeric and crystalline nanoparticles, which provide significant differentiation and added benefits for patients. The company also offers services that support pre-clinical and clinical-stage formulations for clients’ new chemical entities or established branded drugs, facilitating access to next-generation nano-formulated therapies that aim to improve patient outcomes.
Curida
Private Equity Round in 2024
Curida is a pharmaceutical contract development and manufacturing organization that specializes in the production of liquid medicines. The company employs unit-dose Blow-Fill-Seal technology, which enhances product quality and ensures a streamlined manufacturing process with minimal human intervention. In addition to Blow-Fill-Seal products, Curida also manufactures nasal sprays and bottled solutions. By focusing on these specialized services, Curida aims to provide healthcare providers with reliable and tested pharmaceutical products tailored for diverse patient needs.
Paragonix
Series B in 2023
Paragonix Technologies, Inc., established in 2010 and headquartered in Braintree, Massachusetts, is a medical device company specializing in organ preservation and transportation. It develops and manufactures innovative, single-use devices that maintain optimal conditions for donor organs during storage and transport, enhancing post-transplant outcomes. Paragonix's flagship products include the Sherpa Pak systems for hearts, kidneys, and lungs, each designed to provide consistent thermal environments, real-time monitoring, and efficient logistics management. The company's mission is to simplify and improve organ preservation technologies, thereby advancing the field of transplantation medicine.
Laxai Pharma
Acquisition in 2022
Laxai Pharma is a Contract Research Organization offering integrated drug discovery and development services. With global facilities in the United States and India, Laxai provides Medicinal Chemistry, Biology, Process R&D, Analytical Services, Clinical Research, Strategic Resourcing, and Training to biopharmaceutical and agrochemical companies. The company stands out by offering innovative partnership models for efficient research and regulatory compliance.
Juno Pharmaceuticals
Private Equity Round in 2022
Juno Pharmaceuticals is a pharmaceutical company that specializes in the production and distribution of generic and specialty injectable medications. The company focuses on niche markets, offering products such as amoxicillin, hydrochloride syringes, hydromorphone solutions, and phentermine tablets and capsules. Juno Pharmaceuticals is dedicated to providing low-cost pharmaceutical options to medical clinics and hospitals while also promoting smaller brand products through contracted physician partnerships. Its emphasis on injectable drugs positions it as a key player in the market for essential generic medications.
Ascendia Pharmaceuticals
Venture Round in 2021
Ascendia Pharmaceuticals is a contract development and manufacturing organization that specializes in enhancing formulations for preclinical and clinical-stage drug candidates. The company focuses on improving the solubility and bioavailability of poorly water-soluble drugs through its advanced nanotechnology platforms, which include EmulSol for nano-emulsions, AmorSol for amorphous solid dispersions, and NanoSol for nanoparticles. Ascendia provides a comprehensive range of services, including pre-formulation, formulation development, manufacturing, and stability testing for injectable, oral, and topical dosage forms. Additionally, it offers analytical method development and validation services, aimed at addressing complex drug delivery challenges and delivering specialty pharmaceutical products to its clients.
GI Supply
Acquisition in 2020
GI Supply, Inc. is a manufacturer based in Mechanicsburg, Pennsylvania, specializing in innovative endoscopy and paracentesis products tailored for gastroenterologists, colorectal surgeons, and interventional radiologists. Founded nearly 30 years ago by Dr. Frank Jackson, the company aims to address clinical challenges encountered in daily practice. Its product lineup includes endoscopic tattoos, submucosal lifting agents, endoscopic injection needles, endoscope transport bags, bite blocs, and paracentesis management systems. GI Supply's offerings enhance physician efficiency and improve patient satisfaction, with its products currently utilized daily by medical professionals in over 40 countries worldwide.
Smart Medical Systems
Series B in 2018
Smart Medical Systems Ltd. is a medical device company based in Ra’anana, Israel, specializing in gastroenterology and gastrointestinal (GI) endoscopy. The company develops innovative devices aimed at enhancing the practice of GI endoscopy, particularly through its proprietary balloon technology. Its flagship product, the G-EYE endoscope, facilitates Controlled Withdrawal during colonoscopy, improving visibility and efficiency in detecting polyps. In addition to the G-EYE, Smart Medical Systems offers several devices, including the NaviAid Platform, which addresses challenges in GI procedures, and various balloon devices for ileoscopy and colonoscopy. The company is committed to providing cost-effective solutions that benefit both healthcare professionals and patients, and it serves its customers through distributors in the United States and Europe. Smart Medical Systems is also ISO 13485:2003 certified, ensuring a high standard of quality in its product offerings.
Leading Pharma
Venture Round in 2018
Founded in 2014, Leading Pharma manufactures, markets, and distributes generic pharmaceutical products. Its portfolio includes oral solid dose products across various therapeutic areas, sold under the Leading brand to wholesalers, distributors, drugstore chains, mass merchandisers, government agencies, and managed care accounts in the United States.
TELA Bio
Private Equity Round in 2017
TELA Bio is a medical technology company specializing in soft tissue reconstruction. It designs, develops, and markets the OviTex Reinforced Tissue Matrix portfolio for hernia repair and abdominal wall reconstruction, as well as OviTex PR Reinforced Tissue Matrix for plastic and reconstructive surgery and OviTex for laparoscopic and robotic procedures. The reinforced matrices are derived from ovine rumen with polypropylene fiber and are intended to address unmet needs in soft tissue repair while emphasizing preservation of anatomy and minimizing long-term exposure to permanent synthetic materials. The company markets its products through a single direct sales force, principally in the United States. Founded in 2012 and headquartered in Malvern, Pennsylvania.
Pharmaceutics International
Venture Round in 2016
Pharmaceutics International is a science-driven contract development and manufacturing company providing dosage form development and cGMP manufacturing services for biotech and specialty pharmaceutical clients in the United States and internationally. It offers a broad range of dosage forms, including tablets and capsules (hard gelatin and HPMC), soft gels, liquids, inhalations, sterile injectables, and coated beads; it also supports advanced manufacturing technologies such as lyophilization and handling of high-potency compounds, enabling clients to accelerate drug development while meeting regulatory requirements. The company provides pre-formulation and formulation development, clinical trial materials manufacturing, commercial manufacturing, clinical packaging and labeling, and clinical trial kit building and distribution. By integrating scientific insight with product knowledge, it aims to deliver safe, effective medicines and help clients navigate development and scale-up.
Leon Nanodrugs
Series A in 2015
Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through advanced nanotechnology. The company develops a pipeline of improved drug products aimed at increasing the bioavailability of poorly water-soluble medicines. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates both polymeric and crystalline nanoparticles, which provide significant differentiation and added benefits for patients. The company also offers services that support pre-clinical and clinical-stage formulations for clients’ new chemical entities or established branded drugs, facilitating access to next-generation nano-formulated therapies that aim to improve patient outcomes.
Bionpharma
Venture Round in 2015
BionPharma, based in Princeton, New Jersey, with additional offices in Raleigh, North Carolina, specializes in the development and commercialization of affordable quality generic pharmaceuticals. Founded in 2014 by a team of experienced professionals from the generics industry, the company is known for its expertise in product development, regulatory affairs, quality management, sales and distribution, and supply chain management. BionPharma has established itself as one of the largest suppliers of soft gel capsules in the United States, serving both prescription and over-the-counter markets. Through its commitment to building strong partnerships, BionPharma enables clients to access a wide range of generic pharmaceutical products efficiently.
KEW, Inc., established in 2009 and headquartered in Cambridge, Massachusetts, specializes in genomic testing services for cancer patients. The company's core offering, CANCERPLEX, is a precision medicine service that analyzes a patient's genetic drivers to help oncologists select personalized, targeted therapies. KEW's suite of products includes CANCERPLEX FP, a full panel test with immunotherapy options, CANCERPLEX TS for common tumor sites, and CANCERPLEX TX for FDA-approved targeted therapies. The company delivers these solutions through strategic partnerships and distributors, enabling evidence-driven treatment decisions in cancer care.
Sancilio and Company
Venture Round in 2014
Sancilio and Company, founded in 2004 and headquartered in Riviera Beach, Florida, specializes in the development, manufacturing, and distribution of biopharmaceutical products, including over-the-counter items and dietary supplements. The company offers a range of products targeting cardiovascular health, dental health, and women's health. Notable offerings include OCEAN BLUE PROFESSIONAL OMEGA-3 for cardiovascular support and LUDENT SODIUM FLUORIDE CHEWABLE TABLETS for children's dental health. Sancilio also provides a variety of women's health products, such as Mylk, a multivitamin softgel, and Caltranate, a calcium supplement. In addition to its product lines, the company offers pharmaceutical services, encompassing analytical chemistry, formulation development, and contract manufacturing, among others. Despite its comprehensive portfolio, Sancilio and Company filed for Chapter 11 bankruptcy and ceased operations as of May 31, 2019.
Fluxion Biosciences
Series C in 2011
Fluxion Biosciences, founded in 2005, specializes in developing analytical instruments and kits for functional cellular analyses in life science, drug discovery, and diagnostic applications. Its flagship products include the IsoFlux Liquid Biopsy System for enriching rare cell populations like circulating tumor cells, and BioFlux systems for live cell analysis under shear flow, used across various research fields. Additionally, Fluxion offers IonFlux systems for automated patch clamping and provides analytical services for liquid biopsy applications. Serving biotechnology and pharmaceutical companies, academic institutions, and government research organizations, Fluxion distributes its solutions through a network of international distributors, with headquarters in Alameda, California.
Arbor Pharmaceuticals
Series B in 2010
Arbor Pharmaceuticals is a specialty pharmaceutical company based in Raleigh, North Carolina, founded in 2006. It primarily focuses on pediatric medicine, licensing, developing, and commercializing late-stage products designed for common pediatric conditions. The company offers a range of products, including ZINOTIC and ZINOTIC ES for treating Acute Otitis Externa, NEOTIC for pain and inflammation associated with Acute Otitis Media, and XYLAREX for dietary management of Recurrent Acute Otitis Media. Additionally, Arbor Pharmaceuticals provides the Pediaderm HC Complete Kit, specifically formulated to treat and protect the skin of children with atopic dermatitis, commonly known as eczema. The company markets its products through specialized sales forces across the United States, while also engaging in research and development in therapeutic areas like cardiology, neurology, and endocrinology.
Pfenex Inc. is a clinical-stage biotechnology company based in San Diego, California, specializing in the development of protein therapies to address unmet medical needs. The company’s lead product candidate, PF708, aims to serve as a therapeutic equivalent to Forteo for osteoporosis treatment. Additionally, Pfenex is advancing several other candidates, including PF743 and PF745, both of which are recombinant crisantaspase variants, and PF810, a next-generation peptide therapeutic in preclinical development. The company also offers sparX-1 and sparX-2 and has established licensing and supply agreements for CRM197, a modified diphtheria toxin. Central to Pfenex's operations is its proprietary Pfänex Expression Technology, a protein expression platform that utilizes Pseudomonas fluorescens, enabling efficient and rapid identification of high-yield protein production strains across various applications, including therapeutics and vaccines.
SpePharm
Venture Round in 2008
SpePharm is a European specialty pharmaceutical company focused on acquiring, registering, and marketing high-value medicines primarily for the hospital market. The company specializes in oncology, hematology, and supportive care, offering medical products that aid in the local oral treatment and management of complications arising from radiotherapy or chemotherapy. SpePharm's management team possesses extensive global experience in the pharmaceutical sector, with a strong understanding of the European regulatory environment and a particular expertise in niche and orphan products. This strategic focus allows SpePharm to effectively address the needs of healthcare professionals and patients across Europe.
PEAK Surgical
Series C in 2008
PEAK Surgical is a medical device company based in Palo Alto, California, specializing in innovative surgical tools designed to enhance precision and control during surgical procedures. The company offers the PEAK Surgery System, which includes a range of disposable cutting devices that combine the accuracy of a scalpel with the bleeding control typically associated with traditional electrosurgery, minimizing collateral damage. This system is approved for use in various surgical specialties, including general, plastic and reconstructive, ENT, gynecologic, orthopedic, arthroscopic, spinal, and neurological procedures in the United States, as well as for general surgery in the European Union. PEAK Surgical aims to address critical needs in the surgical market by providing advanced solutions that improve patient outcomes.
DIREVO Industrial Biotechnology
Series C in 2007
Direvo Industrial Biotechnology GmbH is a privately owned company based in Cologne, Germany, specializing in the development and marketing of biology-based products and processes for non-pharmaceutical applications. Founded in 2008, the company utilizes its expertise in enzymes, microbes, and process optimization to create bio-based solutions across various sectors, including clean energy, clean chemistry, and biomass conversion. Direvo offers a range of innovative platforms, such as the BluZy portfolio, designed for the grain ethanol industry, which includes products that enhance the nutritional value of bio-ethanol by-products and improve process efficiency in ethanol production. Additionally, the company provides the BluServ platform, focused on automated high-throughput screening for protein and strain engineering, and the BluCon technology platform, which converts non-food feedstocks into carbohydrates for fuel and chemical production. Direvo collaborates with global leaders in the industry to deliver customized solutions tailored to specific market needs.
Alpex Pharma
Series B in 2007
Alpex Pharma SA is a pharmaceutical company based in Mezzovico-Vira, Switzerland, specializing in the research, development, and production of orally dispersible tablets, including effervescent and fast melt formulations. Established in 1983 and formerly known as Aesculapius Pharma SA, the company has developed proprietary technology that enhances the production of these unique tablet forms. Alpex Pharma operates a state-of-the-art facility spanning approximately 7,000 square meters, compliant with good manufacturing practices for both pharmaceutical and nutritional products. The company also offers a range of development services, including drug-excipient compatibility studies, analytical method development, and stability studies, positioning itself as a key player in the global market for fast melt and effervescent tablets.
Atlantis Components
Series D in 2007
Atlantis Components specializes in the design and manufacturing of titanium abutments for implant dentistry, utilizing a proprietary software system known as the Virtual Abutment Design (VAD) system. This innovative system enables technicians to create abutments with unprecedented precision and reliability, enhancing the restoration of dental implants through crown-and-bridge techniques. Atlantis Components' designs are grounded in comprehensive dental research and clinical insights, ensuring that their products meet the needs of dental professionals and improve patient outcomes. The company's commitment to quality and precision positions it as a leader in the field of dental implant solutions.
Cedarburg Hauser Pharmaceuticals
Series A in 2004
Cedarburg Hauser Pharmaceuticals is an experienced contract development and manufacturing organization (CDMO) for active pharmaceutical ingredients (APIs) and intermediates We offer multiple sites for non-GMP R&D projects, GMP kilo labs for early phase projects and GMP plant capacity for late stage and commercial APIs. We apply our drug development experience and expertise to help our clients successfully advance their drug candidate from early preclinical evaluations through clinical trials and eventually to market.